Isreali drugmaker Teva Pharmaceutical Industries has received the regulatory nod in the USA for its Abbreviated New Drug Application for Desmopressin Acetate Tablets, 0.1mg and 0.2mg.
The product is the AB-rated generic equivalent of Aventis’ DDAVP Tablets, which is used for management of central diabetes insipidus, temporary polyuria and polydipsia following head trauma or surgery in the pituitary region, and primary nocturnal enuresis. Total annual sales of the drug, including brand and generic turnover, are around $202 million.
In a separate statement, Teva announced that worldwide in-market sales of the multiple sclerosis drug Copaxone (glatiramer acetate), which is distributed in North America by French drugmaker Sanofi-Aventis, hit $323 million in the fourth quarter, marking a rise of 24% over the year-ago period. This was driven by sales growth of 26% to $220 million in the USA and 19% to $103 million in all other territories.
For the full year, turnover of Copaxone surged 26% to reach a record high of $1.176 million, as sales in the USA jumped 25% to $782 million and revenues from all other territories swelled 27% to $394 million.
